We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Analysis of adverse events leading to dose reduction/interruption of lenvatinib treatment in patients with Child-Pugh B unresectable hepatocellular carcinoma.
- Authors
Kimura, Michio; Asano, Hiroki; Usami, Eiseki; Teramachi, Hitomi; Yoshimura, Tomoaki
- Abstract
Introduction: We aimed to compare the safety of lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (HCC) in patients with Child-Pugh A (CP-A) and Child-Pugh B (CP-B) and to determine the adverse events (AEs) that cause dose reduction/interruption of treatment in patients with CP-B. Methods: Sixty-six patients with lenvatinib as a first-line treatment for HCC at Ogaki Municipal Hospital (Ogaki, Japan) between April 2018 and January 2022 were retrospectively evaluated. We analyzed the treatment duration, AEs, and reasons for dose reduction/interruption associated with lenvatinib treatment in patients with CP-A and CP-B HCC. Results: The CP-B group had significantly more cases of grade ≥ 2 fatigue and anorexia than the CP-A group (p = 0.045 and p = 0.042, respectively). Regarding AEs that caused dose reduction/interruption of treatment, the CP-A group had significantly more cases of proteinuria than the CP-B group (p = 0.015), whereas the CP-B group had significantly more cases of hand-foot syndrome (HFS) than the CP-A group (p = 0.013). Conclusion: Patients with CP-B have greater difficulty than patients with CP-A in continuing treatment with repeated dose reductions/interruption of treatment due to intolerable grade ≥ 2 AEs (fatigue and anorexia). HFS is more likely to cause dose reduction/interruption of treatment in CP-B than in CP-A unresectable HCC.
- Subjects
JAPAN; RETROSPECTIVE studies; TREATMENT duration; PROTEIN-tyrosine kinase inhibitors; RISK assessment; COMPARATIVE studies; DRUG therapy; PROTEINURIA; DRUG side effects; HEPATOCELLULAR carcinoma; PATIENT safety
- Publication
Journal of Oncology Pharmacy Practice, 2023, Vol 29, Issue 7, p1637
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552221145475